Invesco’s Immunic IMUX Stock Holding History

Invesco’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,541	Closed	-$38.6K	–	3806
2025 Q1	$38.6K	Sell	3,541 -140	-4%	-$1.51K	﹤0.01%	3718
2024 Q4	$36.8K	Buy	+3,681	New	+$46.4K	﹤0.01%	3716
2020 Q4	–	Sell	-25,135	Closed	-$4.67M	–	3794
2020 Q3	$4.67M	Buy	+25,135	New	+$4.12M	﹤0.01%	2040
2015 Q3	–	Sell	-1	Closed	-$5K	–	3877
2015 Q2	$5K	Buy	+1	New	+$9.54K	﹤0.01%	4197

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Invesco's IMUX Position: Q2 2025 in Review

Invesco sold out of Immunic (IMUX) in Q2 2025, closing a stake of 3,541 shares — an estimated $38.6K sold.

Invesco first reported a position in IMUX in Q2 2015 and held it in 4 quarters. The position peaked at $4.67M in Q3 2020. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2025.

Invesco reported no remaining Immunic position as of Q2 2025 after selling out during the quarter.
Invesco sold 3,541 Immunic shares in Q2 2025, an estimated $38.6K.
Invesco first reported a position in Immunic in Q2 2015 and held it in 4 quarters.
Invesco's Immunic position peaked at $4.67M in Q3 2020.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.